Department of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, USA.
Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Am J Clin Nutr. 2021 May 8;113(5):1275-1281. doi: 10.1093/ajcn/nqaa381.
Previous studies have related vitamin D supplementation to a lower risk of acute respiratory tract infection. Emerging evidence suggests that vitamin D insufficiency is related to a higher risk of coronavirus disease 2019 (COVID-19) infection.
We aimed to investigate the prospective association between habitual use of vitamin D supplements and risk of COVID-19 infection, and assess whether such an association differed according to the different levels of circulating and genetically predicted vitamin D.
This study included 8297 adults who have records of COVID-19 test results from UK Biobank (from 16 March 2020 to 29 June 2020). The use of vitamin D supplements, circulating vitamin D levels, and main covariates were measured at baseline (2006-2010). Genetically predicted vitamin D levels were evaluated by genetic risk score.
After adjustment for covariates, the habitual use of vitamin D supplements was significantly associated with a 34% lower risk of COVID-19 infection (OR, 0.66; 95% CI, 0.45-0.97; P = 0.034). Circulating vitamin D levels at baseline or genetically predicted vitamin D levels were not associated with the risk of COVID-19 infection. The association between the use of vitamin D supplements and the risk of COVID-19 infection did not vary according to the different levels of circulating or genetically predicted vitamin D (P-interactions = 0.75 and 0.74, respectively).
Our findings suggest that habitual use of vitamin D supplements is related to a lower risk of COVID-19 infection, although we cannot rule out the possibility that the inverse association is due to residual confounding or selection bias. Further clinical trials are needed to verify these results.
先前的研究表明,维生素 D 补充剂与急性呼吸道感染风险降低有关。新出现的证据表明,维生素 D 不足与 2019 年冠状病毒病(COVID-19)感染风险增加有关。
我们旨在研究习惯性使用维生素 D 补充剂与 COVID-19 感染风险之间的前瞻性关联,并评估这种关联是否因循环和遗传预测的维生素 D 水平不同而有所不同。
这项研究纳入了 UK Biobank 中有 COVID-19 检测结果记录的 8297 名成年人(从 2020 年 3 月 16 日至 2020 年 6 月 29 日)。维生素 D 补充剂的使用、循环维生素 D 水平和主要混杂因素在基线(2006-2010 年)进行测量。遗传预测的维生素 D 水平通过遗传风险评分进行评估。
在调整混杂因素后,习惯性使用维生素 D 补充剂与 COVID-19 感染风险降低 34%显著相关(OR,0.66;95%CI,0.45-0.97;P=0.034)。基线时的循环维生素 D 水平或遗传预测的维生素 D 水平与 COVID-19 感染风险无关。维生素 D 补充剂的使用与 COVID-19 感染风险之间的关联与循环或遗传预测的维生素 D 水平无关(P 交互作用=0.75 和 0.74)。
我们的研究结果表明,习惯性使用维生素 D 补充剂与 COVID-19 感染风险降低有关,尽管我们不能排除这种负相关可能是由于残余混杂或选择偏倚所致。需要进一步的临床试验来验证这些结果。